Academic Journals Database
Disseminating quality controlled scientific knowledge

Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine

Author(s): Lisa L. Ross | Marjorie D. Robinson | Giampiero Carosi | Adriano Lazzarin | Hans-Juergen Stellbrink | Graeme Moyle | Naomi Givens | William G. Nichols

Journal: Drugs and Therapy Studies
ISSN 2038-9493

Volume: 2;
Issue: 1;
Start page: e1;
Date: 2012;
Original page

Keywords: HIV-1 | fosamprenavir | resistance | mutations | subtype

The impact of HIV-1 subtype on resistance mutation selection and on virologic response to fosamprenavir in combination with once-daily (QD) versus twice-daily (BID) dosing of ritonavir was examined in a prospective, open label, randomized study in antiretroviral-naïve, HIV-1 infected subjects. We studied APV109141 compared QD fosamprenavir/ritonavir (1400mg/100mg) to BID fosamprenavir/ritonavir (700mg/100mg), administered in combination with a QD fixed-dose abacavir/lamivudine (600 mg/300 mg) combination tablet through 48 weeks in ART-naïve subjects. HIV genotypes were obtained from all subjects at screen. Subjects with virologic failure (VF) were also genotyped at baseline and VF. HIV subtypes observed in the ITT (n=214) population were A or AE or AG circulating recombinant forms (CRFs) 19%; B 62%; BF or BG CRFs 2%; C or CPX CRFs 7%; D 2%; F1 7%; G

Tango Rapperswil
Tango Rapperswil

     Save time & money - Smart Internet Solutions